• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient.

作者信息

Brauchli Yolanda B, Wais Thomas, Gratwohl Alois, Heim Dominik, Schipf Alexander, Diebold Joachim, Krähenbühl Stephan

出版信息

Acta Oncol. 2010 May;49(4):523-5. doi: 10.3109/02841861003691952.

DOI:10.3109/02841861003691952
PMID:20307244
Abstract
摘要

相似文献

1
Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient.一名60岁男性患者在尼罗替尼治疗期间发生致命性心肌梗死。
Acta Oncol. 2010 May;49(4):523-5. doi: 10.3109/02841861003691952.
2
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.尼洛替尼300毫克每日两次用于对既往酪氨酸激酶抑制剂不耐受的慢性期慢性髓性白血病患者的疗效和安全性：IIIb期ENESTswift研究结果
Leuk Res. 2018 Apr;67:109-115. doi: 10.1016/j.leukres.2018.02.013. Epub 2018 Feb 21.
3
[Management of chronic myeloid leukemia].[慢性髓性白血病的管理]
Rinsho Ketsueki. 2008 Oct;49(10):1401-10.
4
Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.用酪氨酸激酶抑制剂尼罗替尼治疗的t(9;22)(q34;q11)阳性慢性髓性白血病患者发生大疱性Sweet综合征：BCR-ABL阳性病变细胞的间期细胞遗传学检测
Arch Dermatol. 2008 Mar;144(3):361-4. doi: 10.1001/archderm.144.3.361.
5
The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.尼洛替尼治疗的慢性髓性白血病患者中白细胞介素-1β与急性心肌梗死的关联：横断面研究
Ann Hematol. 2020 Feb;99(2):359-361. doi: 10.1007/s00277-019-03896-4. Epub 2019 Dec 23.
6
[Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].[胃肠道间质瘤治疗中对酪氨酸激酶抑制剂的耐药性。新的治疗可能性出现]
Lakartidningen. 2009;106(50-51):3424-9.
7
Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.超越深度分子反应的舒适区：慢性髓性白血病主要分子反应中的停药
Leuk Lymphoma. 2019 Dec;60(13):3330-3332. doi: 10.1080/10428194.2019.1622103. Epub 2019 Jun 4.
8
Pulmonary toxicities of tyrosine kinase inhibitors.酪氨酸激酶抑制剂的肺部毒性。
Clin Adv Hematol Oncol. 2011 Nov;9(11):824-36.
9
T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.一名接受尼洛替尼治疗的慢性髓性白血病患者发生T细胞原淋巴细胞白血病：首例文献报道
J Clin Pathol. 2019 Jul;72(7):511-512. doi: 10.1136/jclinpath-2019-205799. Epub 2019 Apr 19.
10
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.尼洛替尼与伊马替尼治疗新诊断的费城染色体阳性慢性期慢性髓性白血病患者：3 期随机 ENESTnd 试验的 24 个月最小随访。
Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17.

引用本文的文献

1
Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge.接受化疗患者的缺血性冠心病管理：一项未知的临床挑战。
Future Cardiol. 2017 May;13(3):247-257. doi: 10.2217/fca-2017-0002. Epub 2017 Jun 1.
2
Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.癌症治疗的血管毒性：新旧情况——一条不断演变的途径
Circulation. 2016 Mar 29;133(13):1272-89. doi: 10.1161/CIRCULATIONAHA.115.018347.
3
Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria.
采用离体鼠肝线粒体多参数检测法预测化学物质诱导的肝损伤。
Toxicol Sci. 2012 Oct;129(2):332-45. doi: 10.1093/toxsci/kfs197.